Results 191 to 200 of about 32,621 (262)
How does high-refractive error affect quantitative pupillometry values? [PDF]
Indian J OphthalmolKocabas DÖ, Yavrum F.
europepmc +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Health economics evaluation of screening for sarcopenia among community-dwelling older persons. [PDF]
BMC Public HealthLiu Y +7 more
europepmc +1 more source
British Journal of Clinical Pharmacology, EarlyView.Feedback is the most powerful driver of learning, but it can afford variable effects depending on the method used. The design of feedback for computer‐based assessment—now increasingly prevalent in higher education—remains relatively underexplored, particularly for pharmacology education.
Claire Y. Hepburn
wiley +1 more source
The smog of exercise: the causal effect of air pollution on fitness behaviors. [PDF]
Front Public HealthCao W, Gao T, Ao C, Xiong H, Li N.
europepmc +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Intelligent Vehicle Target Detection Algorithm Based on Multiscale Features. [PDF]
Sensors (Basel)Li A, Ning X, Zöldy M, Chen J, Xu G.
europepmc +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola +5 more
wiley +1 more source